Plastic Surgery Doctors in Round Rock, TX Accepting Medicare

4 Plastic Surgery doctors found. Showing 1 - 4

Dr. Troy D Thompson, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 Round Rock Ave, Suite 200, Round Rock, TX 78681 Phone: 512-341-2800    Fax: 512-341-2801

Amy Louise Sanders Bekanich, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 170 Deepwood Dr, Suite 102, Round Rock, TX 78681 Phone: 512-244-1444    Fax: 512-244-1445

Dr. Staci Jeanine Hix-hernandez, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 University Blvd, Dept Of Plastic Surgery, Round Rock, TX 78665 Phone: 512-509-0200

Dr. Ross Michael Blagg, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 7700 Cat Hollow Drive, Suite 103, Round Rock, TX 78681 Phone: 512-244-1444

News Archive

Sex-until-after-marriage programs in the United States have been ineffective study shows

Two research papers have been released that show that the abstinence-only-until-marriage (AOUM) programs and policies in the United States are ineffective by and large and have not been successful in reducing risky sexual behaviors or early initiation of sex. Studies have reported that these are programs that successfully withhold medically accurate information not to mention infringe on adolescent human rights and reinforce gender stereotypes. The findings are published in the Journal of Adolescent Health.

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Catalyst Pharmaceutical Partners, Inc. today announced that its investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, has been granted orphan-drug designation for the treatment of infantile spasms (West Syndrome) by the U.S. Food and Drug Administration (FDA).

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, are providing their second bi-weekly Default Status Report under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.

Midwifery care costs less and just as safe as standard maternity care

Continued care from a named midwife throughout pregnancy, birth, and after the baby is born (caseload midwifery) is just as safe as standard maternity care (shared between different midwives and medical practitioners) for all women irrespective of risk, and is significantly cheaper, according to new research published in The Lancet.

Read more Medical News

› Verified 6 days ago